{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:06:10Z","timestamp":1725548770929},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.ijrobp.2005.11.003","type":"journal-article","created":{"date-parts":[[2006,2,11]],"date-time":"2006-02-11T12:14:40Z","timestamp":1139660080000},"page":"1299-1307","source":"Crossref","is-referenced-by-count":8,"title":["Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources"],"prefix":"10.1016","volume":"64","author":[{"given":"Gary L.","family":"Dillehay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"Ellerbroek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Balon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Brill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry W.","family":"Grigsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger M.","family":"Macklis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Mauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq A.","family":"Mian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Potters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward B.","family":"Silberstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey C.Y.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie E.","family":"Gaspar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2005.11.003_fr1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/0090-8258(85)90266-5","article-title":"Complications from intraperitoneal radioactive phosphorus in ovarian malignancies","volume":"21","author":"Bakri","year":"1985","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr2","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1210\/jc.2003-030298","article-title":"Radioiodine treatment with 30 mCi after recombinant effectiveness for postsurgical remnants ablation","volume":"88","author":"Barbaro","year":"2003","journal-title":"J Endocrinol Metab"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0360-3016(97)00927-9","article-title":"Radiotherapeutic management of osseous metastases","volume":"40","author":"Ben-Josef","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF03343960","article-title":"Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid stimulating hormone","volume":"25","author":"Berg","year":"2002","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr5","unstructured":"BEXXAR prescribing information, Glaxo Smith Kline and Corixa Corporation."},{"key":"10.1016\/j.ijrobp.2005.11.003_fr6","first-page":"79","article-title":"Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone","volume":"2","author":"Brundage","year":"1998","journal-title":"Cancer Prev Control"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr7","first-page":"206","article-title":"Radiation safety when a patient dies after therapy","volume":"26","author":"Bybel","year":"1998","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1210\/jc.85.1.175","article-title":"Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?","volume":"85","author":"Cailleux","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr9","first-page":"1198","article-title":"Absence of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I","volume":"41","author":"Cholewinski","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr10","first-page":"1868","article-title":"Therapeutic I-131 in outpatients","volume":"41","author":"Coover","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr11","first-page":"1402","article-title":"Radiation safety considerations for post-iodine-131 thyroid cancer therapy","volume":"33","author":"Culver","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0090-8258(81)90149-9","article-title":"Radioactive chromic phosphate suspension","volume":"12","author":"Currie","year":"1981","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr13","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1001\/jama.283.17.2272","article-title":"Radiation exposure from outpatient radioactive iodine (131I) therapy for thyroid carcinoma","volume":"283","author":"Grigsby","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr14","first-page":"567","article-title":"Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1\u20133 weeks of thyroxine discontinuation","volume":"45","author":"Grigsby","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr15","series-title":"Nuclear medicine therapy","author":"Harbert","year":"1987"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr16","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJM199805143382007","article-title":"Treatment of benign nodular thyroid disease","volume":"338","author":"Hermus","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr17","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1628::AID-CNCR13>3.0.CO;2-1","article-title":"Radiation for bone metastases","volume":"80","author":"Janjan","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s002770050576","article-title":"Therapy of B-cell lymphomas with monoclonal antibodies and radioimmunoconjugates","volume":"79","author":"Johnson","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr19","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1182\/blood.V96.4.1259","article-title":"Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma","volume":"96","author":"Kaminski","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr20","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO.1988.6.8.1254","article-title":"Early stage ovarian cancer: A randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: A National Cancer Institute of Canada Clinical Trails Group report","volume":"6","author":"Klassen","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr21","first-page":"457","article-title":"Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma","volume":"2","author":"Knox","year":"1996","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr22","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s002590000315","article-title":"Treatment of bone metastases of prostate cancer with strontium-89 chloride","volume":"27","author":"Kraeber-Bodere","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr23","first-page":"594","article-title":"Radioimmunotherapy of lymphomas and leukemias","volume":"Vol. 1","author":"Kuzel","year":"1996"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/jc.2002-020805","article-title":"A randomized comparison of raidoiodine doses in Graves\u2019 hyperthyroidism","volume":"88","author":"Leslie","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr25","first-page":"74","article-title":"Pediatric thyroid nodules","volume":"90","author":"Lugo-Vicente","year":"1998","journal-title":"Bol Asoc Med P R"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr26","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1210\/jc.86.4.1447","article-title":"Clinical review 128","volume":"86","author":"Mazzaferri","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S1053-4296(00)80047-8","article-title":"Use of radionuclides for the palliation of bone metastases","volume":"10","author":"McEwan","year":"2000","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr28","first-page":"28","article-title":"Program-specific guidance about medical use licenses","volume":"15","year":"2004","journal-title":"NUREG"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2265.1999.00635.x","article-title":"Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules","volume":"50","author":"Nygaard","year":"1999","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr30","first-page":"1418","article-title":"Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine","volume":"35","author":"Pacini","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr31","first-page":"639","article-title":"The role of radioisotopes in radiation oncology","volume":"24","author":"Park","year":"1997","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0090-8258(89)90631-8","article-title":"Intraperitoneal chromic phosphate in ovarian cancer","volume":"32","author":"Potter","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr33","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood.V83.5.1390.1390","article-title":"Retention of B-cell-specific monoclonal antibodies by human lymphoma cells","volume":"83","author":"Press","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","article-title":"A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer","volume":"31","author":"Quilty","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr35","first-page":"1482","article-title":"A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation","volume":"43","author":"Robbins","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr36","first-page":"44","article-title":"Clinical experience with strontium-89 in prostatic and breast cancer patients","volume":"20","author":"Robinson","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr37","first-page":"907","article-title":"Outpatient treatment with (131) I anti-B1 antibody","volume":"42","author":"Rutar","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr38","first-page":"354","article-title":"A practical methodology for patient release after tositumomab and (131) I-tositumomab therapy","volume":"43","author":"Siegel","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr39","first-page":"993","article-title":"Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging","volume":"79","author":"Soper","year":"1992","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0002-9378(85)90112-7","article-title":"Intraperitoneal chromic phosphate P32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma","volume":"153","author":"Soper","year":"1985","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr41","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1148\/radiology.146.2.6849103","article-title":"Observations on the intraperitoneal distribution of chromic phosphate (32P) suspension for intraperitoneal therapy","volume":"146","author":"Sullivan","year":"1983","journal-title":"Radiology"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr42","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3109\/02841869609101653","article-title":"A Monte-Carlo program converting activity distributions to absorbed dose distributions in a radionuclide treatment planning system","volume":"35","author":"Tagesson","year":"1996","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr44","series-title":"Nuclear medicine in clinical practice","article-title":"Endocrine therapy","author":"Thrall","year":"1982"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr45","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/1097-0142(19850215)55:4<794::AID-CNCR2820550418>3.0.CO;2-Z","article-title":"Long-term results and prognostic factors in patients with differentiated thyroid carcinoma","volume":"55","author":"Tubiana","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr46","series-title":"Diagnostic nuclear medicine","first-page":"653","article-title":"Radioiodine treatment of thyroid disease","author":"Tuttle","year":"2003"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1089\/thy.1999.9.387","article-title":"Short-term effectiveness of low-dose radioiodine ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer","volume":"9","author":"Vermiglio","year":"1999","journal-title":"Thyroid"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr48","first-page":"267","article-title":"Administration guidelines for radioimmunotherapy of non-Hodgkin\u2019s lymphoma with (90) Y-labeled anti-CD20 monoclonal antibody","volume":"43","author":"Wagner","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr49","first-page":"14S","article-title":"Patient-specific whole-body dosimetry","volume":"39","author":"Wahl","year":"1998","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr50","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin\u2019s lymphoma","volume":"44","author":"Wiseman","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr51","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.10305","article-title":"Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin\u2019s lymphoma","volume":"94","author":"Wiseman","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr52","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr53","first-page":"1021","article-title":"Adjuvant therapy in stage I and stage II epithelial ovarian cancer","volume":"322","author":"Young","year":"1990","journal-title":"I"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr54","series-title":"Zevalin (ibritumomab tiuxetan) prescribing information","year":"2002"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.semnuclmed.2003.11.005","article-title":"Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin)","volume":"34","author":"Zhu","year":"2004","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.ijrobp.2005.11.003_fr56","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1053\/j.semnuclmed.2003.11.001","article-title":"Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)","volume":"34","author":"Zimmer","year":"2004","journal-title":"Semin Nucl Med"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301605028749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301605028749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T16:37:31Z","timestamp":1586709451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301605028749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0360301605028749"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2005.11.003","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}